High-dose chemotherapy (HDCT) followed by autologous blood stem cell transplantation is considered the treatment of choice for patients with relapsed or resistant aggressive non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD). However, several authors report failure of standard mobilization regimens in 29% to 56% of these patients making the completion of HDCT impossible and as a result, negatively influencing long-term outcome. High-dose chemotherapy (HDCT) followed by peripheral blood stem cell transplantation (PBSCT) is being increasingly used in patients with malignancies. However, there
are no standard regimens for inducing mobilization of peripheral blood stem cells (PBSC) based on randomized comparisons. In patients with malignant lymphomas, cyclophosphamide at different dose levels ranging from 1.5 to 7 g/m 2 followed by granulocyte colony-stimulating factor (G-CSF) at doses of 5 to 10 g/kg/day is mainly used to mobilize PBSC. [1] [2] [3] Stem cells are harvested by leukapheresis to collect at least 2.0 ϫ 10 6 CD34 + cells/kg. Various factors influencing the stem cell yield have been identified, eg tumor type, stage of disease, pretreatment, 4 interval between drug courses, 5, 6 prior radiotherapy, dose of G-CSF and chemotherapy used for PBSC mobilization. [7] [8] [9] [10] Mobilization is more effective in patients at diagnosis as compared to patients with resistant or relapsed disease. 8 The diagnosis of malignant lymphoma and in particular Hodgkin's disease has been associated with a poor mobilization efficacy. 4 Thus, the use of currently available mobilization protocols does not ensure adequate PBSC mobilization in pretreated lymphoma patients. In this situation autologous bone marrow cells, alone or mixed with PBSC, may be used to allow treatment with HDCT. Since the results of autologous bone marrow transplantation (ABMT) are proven inferior to PBSCT in terms of time to engraftment and infectious complications, the use of PBSC is preferred by most centers. 11, 12 To investigate a different mobilization strategy, we used etoposide in patients with relapsed or resistant lymphoma. Here, we report on 16 patients with multiple risk factors for low stem cell yield who failed a first cycle of high-dose cyclophosphamide. After a second mobilization attempt with high-dose etoposide all patients were successfully mobilized and proceeded to high-dose chemotherapy without autologous bone marrow harvest.
Patients and methods

Patient characteristics and treatment protocol
Between August 1997 and October 1998, etoposide mobilization was evaluated in all consecutive patients who had failed an initial cyclophosphamide mobilization. The patient characteristics are summarized in Table 1 . Eight male and eight female patients with a median age of 40 years (range 22-68) entered this study. Histology was reassessed by lymph node biopsy at relapse according to the REAL-classification. Eight patients with Hodgkin's disease and eight patients with non-Hodgkin's lymphoma had failed to respond to first-line chemotherapy or had relapsed after achieving a complete response. Eleven patients received a new high-dose sequential protocol with two initial cycles of DHAP (cisplatin, cytarabine, dexamethasone) 13 and five patients received the Dexa-BEAM protocol with two initial cycles of Dexa-BEAM (dexamethasone, BCNU, melphalan, etoposide and cytarabine).
14,15 DHAP and Dexa-BEAM were repeated after 14 or 29 days, respectively. After achieving CR or PR patients received high-dose cyclophosphamide (4 g/m 2 ) followed by G-CSF (2 ϫ 5 g/kg) in order to mobilize peripheral blood stem cells. After DHAP all 11 patients were consecutively treated with high-dose methotrexate (8 g/m 2 ) plus vincristine (1.4 mg/m 2 ) and after hematological reconstitution with high-dose etoposide 500 mg/m 2 (days 1-4) as 8-h infusion plus G-CSF (2 ϫ 5 g/kg). The five patients treated with the Dexa-BEAM regimen received high-dose etoposide after mobilization failure with cyclophosphamide. Six patients with Hodgkin's disease and five patients with high-grade non-Hodgkin's lymphoma entered the high-dose sequential protocol. Three patients with lowgrade NHL and two patients with HD at second relapse were treated according to the Dexa-BEAM protocol. Eight of 16 patients had advanced disease (stage III and IV). Overall, patients were intensively pretreated with aggressive combination chemotherapy and a median of eight cycles (range 1-11) of different regimens. 38% (6/16) of the patients had prior radiotherapy. Six patients had failed to achieve CR after initial first-or second-line treatment and 10 patients were in their first remission.
PBSC harvesting
Leukocyte count was monitored daily after mobilization chemotherapy and the percentage of CD34 + cells was assessed when leukocytes were Ͼ1000/l. Leukaphereses were performed when CD34 + cell counts reached more than 10 cells/l. The blood volume of each patient was routinely processed three times by using the Cobe Spectra (Lakewood, CO, USA) or the Fresenius AS 104 cell separator (St Wendel, Germany) according to the manufacturer's recommendations to collect at least 2 ϫ 10 6 CD34 + cells/kg. Leukapheresis was stopped on the day the CD34 + cell count declined and a single large volume apheresis resulted in less than 0.4 ϫ 10 6 CD34 + cells/kg. Leukocyte surface phenotype analysis using flow cytometry was performed as previously reported. 16 Mononuclear cells were stained with fluorescein isothiocyanate (FITC)-and phycoerythin (PE)-conjugated CD34 (anti-HPCA-2, Becton Dickinson, San Jose, CA, USA) monoclonal antibodies with mouse IgG as a negative control and counterstaining was performed with anti-CD45. More than 20 000 cells were analyzed with flow cytometry using a FACScan flow cytometer (Becton Dickinson) with Cellquest software. The frequency of colony-forming hematopoietic progenitor cells was evaluated as previously described. 17 Patients were considered mobilization failures if the CD34 + cell count did not reach Ͼ10 cells/l or if stem cell harvest was below 2.0 ϫ 10 6 /kg. Statistical analyses were performed using the Wilcoxon matched-pairs signed-rank test (SPSS version 6.1.3, SPSS Inc, Chicago, IL, USA).
Results
Overall, 16 patients were treated with high-dose cyclophosphamide 4 g/m 2 and failed to mobilize adequate numbers of peripheral blood stem cells. Individual risk factors influencing stem-cell mobilization and mobilization outcome including pretreatment and time interval between last chemotherapy are summarized in Table 2 + cells/kg, respectively). Overall, mobilization with cyclophosphamide + G-CSF resulted in a median progenitor yield of 0.0 ϫ 10 6 CD34 + cells/kg (range 0-1.0) and 0.0 ϫ 10 4 CFU-GM/kg (range 0-20.9) in those 16 patients. Toxicity of cyclophosphamide was mainly hematological. All patients experienced WHO grade IV leukocytopenia (leukocytes Ͻ1000/l) and thrombocytopenia (platelets Ͻ25 000/l) with a median duration of 5.0 (range 3-8) and 5.0 (range 3-9) days, respectively. Patients received cyclophosphamide for mobilization at a median of 25 days (range 19-147) after the last cycle of induction treatment. The median time interval between cyclophosphamide and etoposide mobilization was 39 days (range . In this respect, there was no difference for patients treated according to the high-dose sequential protocol and patients treated with the Dexa-BEAM regimen (median 40 days (range 25- + cells for each day after mobilization are shown in Figure 1 .
The maximum increase of PBSC occurred between days 13-15, following cyclophosphamide and days 15-17 after etoposide, therapy. After etoposide 15/24 leukaphereses were performed between day 14 and 16 ( Figure 2 ). In each individual patient, the maximum number of peripheral CD34
+ cells was higher after etoposide as compared to cyclophosphamide. Peak values of peripheral CD34 + cells for all 16 patients are shown in Figure 3 .
A comparison of CD34 + cells was performed in five additional patients not included in this report who were successfully mobilized with cyclophosphamide. Interestingly, rebound increase in PBSC showed higher peak values of CD34 + cells after etoposide as compared to cyclophosphamide (median: 37.2/l vs 125.4; P = 0.1441).
Toxicity after high-dose etoposide was evaluable for all patients. Non-hematological toxicity was moderate with one WHO grade III infection due to septicemia in therapyinduced myelosuppression. All but one patient experienced WHO grade IV leukocytopenia and thrombocytopenia with a median duration of 6.0 (range 3-9) and 6.0 (range 3-10) days, respectively (Table 4) . Platelet transfusions were necessary in 13/16 patients (median 2.0; range 0-4), and 14/16 received red blood cell transfusions (median 2.0; range 0-6). Until October 1998, 13/16 patients received high-dose chemotherapy. Median time of leukocytopenia (leukocytes Ͻ1000/l) was 10 days (8-11) and median time to last platelet transfusion after the beginning of BEAM was 18 days (13-31). These data compare favourably to engraftment patterns described for conventional mobilized PBSC.
Discussion
The following findings emerge from this study: (1) . (4) The use of high-dose etoposide permitted the collection of sufficient numbers of CD34 + cells in all 16 patients who had failed initial cyclophosphamide mobilization. The toxicity of etoposide 2 g/m 2 was mainly hematological, with WHO grade IV leukocytopenia and thrombocytopenia and with a median duration of 6.0 (3-9) and 6.0 (3-10) days, respectively. Nonhematological toxicity was mild, with one WHO grade III infection and moderate mucositis. Therefore, we consider etoposide mobilization feasible without severe side-effects. After etoposide mobilization PBSC quality appeared not to be impaired. 13/16 patients were successfully transplanted with normal engraftment patterns.
HDCT followed by autologous stem cell support is considered the treatment of choice for patients with relapsed or refractory NHL or HD as suggested by the results of randomized trials performed by the PARMA group, 18 the British National Lymphoma Investigation, 19 and the German Hodgkin Study Group. 20 Autologous stem cells are routinely harvested by leukapheresis after chemotherapyinduced marrow aplasia with a target yield of Ͼ2.0 ϫ 10 6
CD34
+ cells/kg. A variety of different mobilization regimens has been described. The combination of chemotherapy and growth factors such as G-CSF or GM-CSF is the most efficient way to mobilize stem cells. 21 In the present study, we report on a group of 16 heavily pretreated lymphoma patients who failed initial mobilization with high-dose cyclophosphamide (4 g/m 2 ) and G-CSF at a dose of 2 ϫ 5 g/kg. All 16 patients were intensively pretreated with aggressive combination chemotherapy and a median of eight cycles (range 1-11) of different regimens. Six of 16 patients were refractory to prior treatment and 6/16 (38%) of the patients had prior radiotherapy. In addition, although the DHAP regimen (dexamethasone, cytarabine, cisplatin) used in 11/16 patients prior to cyclophosphamide does not consist of stem cell toxic drugs, the short interval between the two DHAP cycles (median 16 days) may have adversely influenced stem cell yields in these patients. Five of 16 patients received Dexa-BEAM which contains the stem cell-toxic drugs BCNU and melphalan. The number of Dexa-BEAM cycles has been shown to be the predominate prognostic factor affecting CD34
+ cell yield in a study of 96 patients reported by Dreger et al. 10 High-dose cyclophosphamide followed by G-CSF has gained favor as the preferred chemotherapy agent for mobilization. The dose given varies from 1.5 to 7.0 g/m 2 and 2-4 g/m 2 is used by most groups. Although very effective in the vast majority of patients, a substantial proportion of patients fail to mobilize adequate numbers of PBSC. Mobilization has been reported to be particularly difficult in patients with relapsed or primary refractory lymphoma. Tarella et al 8 assessed the mobilization of 48 patients with non-Hodgkin's lymphoma or Hodgkin's disease. PBSC mobilization was significantly higher in patients at first diagnosis compared with refractory and relapsed patients (median peak values of CD34 + cells: 286/l vs 47/l, P = 0.0001). Only 15/27 (56%) patients under salvage treatment with HDCT were able to complete PBSC autografting.
McQuaker et al 22 report a 29% failure to achieve adequate mobilization in a group of 50 patients with relapsed or resistant lymphoma after cyclophosphamide 3-4 g/m 2 .
There is some evidence that higher doses of cyclophosphamide result in higher PBSC yields, and higher doses of G-CSF have a similar effect. 23 Although cyclophosphamide 7 g/m 2 may represent a useful mean of increasing collection of PBSC, the toxicity is considerable with occurrence of fatal complications in 2/21 patients. 24 The collection of bone marrow cells under general anesthesia may be successful in some of those patients who have failed mobilization of peripheral stem cells. Since ABMT has been shown to be inferior to PBSCT in terms of time to engraftment and infectious complications, 11, 12 alternative mobilization strategies are needed.
There are few studies that compare the efficacy of PBSC mobilization with different chemotherapy protocols. In myeloma patients, 7 g/m 2 cyclophosphamide was more effective as compared with 4 g/m 2 . 25 In patients with breast cancer, combination chemotherapy regimens were superior to single-agent cyclophosphamide for the mobilization of CD34 + cells, 26 and in lymphoma patients a combination of ifosphamide, etoposide, and epirubicin (IVE) resulted in a significantly higher median yield of CD34 + cells (8.62 ϫ 10 6 /kg) compared with cyclophosphamide plus G-CSF (3.59 ϫ 10 6 /kg) (P = 0.045). 22 High-dose etoposide has been previously reported to be effective in lymphoma patients. 27 Why etoposide mobilization resulted in a 100% successful harvest of PBSC in our patients remains unclear. There was no difference in the time interval between last induction chemotherapy and cyclophosphamide mobilization (25 days; range 19-147) and the time interval between cyclophosphamide and etoposide mobilization (39 days; range 25-65); P = 0.1554. Etoposide mobilization was successful after a prior non-stem cell toxic regimen (DHAP) as well as after a stem cell toxic regimen (Dexa-BEAM). Compared with cyclophosphamide, etoposide is less commonly used as a component of conventional first-line therapy. Therefore etoposide may lack cross-resistance with cyclophosphamide, but there are no data from the literature concerning an increased mobilization efficacy. Finally, sideeffects of high-dose cyclophosphamide and etoposide were mainly hematological with a median duration of leukocytopenia WHO grade IV of 5.0 and 6.0 days, respectively. Although only slightly more toxic, etoposide produced a significantly higher rebound increase in PBCS in all patients allowing the collection of at least 2.0 ϫ 10 6 CD34 + in 44% of the patients with a single leukapheresis.
In conclusion, our study is the first intraindividual comparison of the mobilization efficacy of cyclophosphamide and etoposide in 16 patients with relapsed or resistant lymphoma. Etoposide mobilized significantly more CD34 + cells than cyclophosphamide. Furthermore, in all 16 patients who had failed initial cyclophosphamide mobilization, the use of etoposide enabled us to collect sufficient numbers of CD34 + cells avoiding the collection of bone marrow under general anesthesia. Etoposide 2 g/m 2 is an effective and safe mobilization regimen and may be used in patients who have failed standard cyclophosphamide 4 g/m 2 mobilization. To evaluate further the role of etoposide in stem cell mobilization, a prospective randomized trial comparing the two mobilization regimens is required.
